Drug Discovery

Nanobac is dedicated to the discovery and development of prescription pharmaceuticals that target Calcifying Nanoparticles and inhibit, destroy or neutralize them.

CNPs offer a unique model for studying many diseases involving soft tissue calcification or plaque. We have developed drug screening assays using this model to screen compounds using proprietary in vitro screening assays.

The Company also applies its proprietary systems to test partner's compounds.

Our business strategy is to develop and license therapies to address the unmet needs of patients in the cardiovascular and urological disease markets.

Our development strategy is to enter into partnerships with pharmaceutical and biotechnology partners who have the capability and infrastructure to successfully market products around the world.

Nanobac is interested in discussing opportunities for strategic alliances with pharmaceutical and biotechnology companies.

For more information, please contact .

Nanobac Pharmaceuticals, Inc.
3000 Bayport Drive, Suite 910
Tampa, Florida 33607
Ph. (813) 865-1125

Email us at: